Arkadiusz Z. Dudek, M.D., Ph.D.

Open

• A Randomized, Phase 2/3, Open-Label Study To Investigate The Efficacy And Safety Of RP2 In Combination With Nivolumab Versus Ipilimumab In Combination With Nivolumab In Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma Jacksonville, FL Rochester, MN

  The purpose of this study is to compare the effect of RP2 + nivolumab relative to ipilimumab + nivolumab on overall survival (OS) and  to compare the effect of RP2 + nivolumab relative to ipilimumab + nivolumab on progression free survival (PFS).